Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B
NCT06636175Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 64cu-llp2a in multiple myeloma (MM) and lymphoma (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Organ dosimetry of participants up to 2 days and Safety and tolerability of new formulation of 64Cu-LLP2A up to 7 days. Started Mar 2025; status: terminated.
02
Drugs
64cu-llp2a
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NCT06636175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636175.